Metastatic Colorectal Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Amgen, Pfizer, Nurix Therapeutics Inc, Sumitomo Dainippon Pharma Oncology, Novocure, Pr

Metastatic Colorectal Cancer Pipeline constitutes 80+ key companies continuously working towards developing 100+ Metastatic Colorectal Cancer treatment therapies, analyzes DelveInsight.

Metastatic Colorectal Cancer Overview:

Metastatic colorectal cancer (mCRC) is a type of cancer that starts in the colon and spreads to other parts of the body, most commonly the liver, lungs, and peritoneum. It represents the advanced stage of colorectal cancer and is a leading cause of cancer-related deaths globally. Early detection and treatment are vital, but many cases are diagnosed at later stages due to the lack of symptoms in the early stages of the disease. The symptoms of metastatic colorectal cancer can vary based on the organs affected. Common signs include changes in bowel habits (such as diarrhea or constipation), rectal bleeding, abdominal pain, and unexplained weight loss. If the cancer has spread to the liver, symptoms may include jaundice, an enlarged liver (hepatomegaly), and pain in the upper right abdomen. If it has spread to the lungs, symptoms may include cough, shortness of breath, and chest pain. General symptoms like fatigue and weakness are also common.

The development of colorectal cancer is influenced by multiple factors, including genetic predisposition, environmental influences, and lifestyle choices. Risk factors include a family history of colorectal cancer, inflammatory bowel disease, a diet high in red and processed meats, obesity, smoking, and excessive alcohol consumption. On a molecular level, colorectal cancer progression involves genetic mutations that drive uncontrolled cell growth, invasion, and metastasis. Key pathways involved include the Wnt signaling pathway, mutations in the APC gene, and changes in the KRAS, NRAS, and BRAF genes.

Request for a detailed insights report on Metastatic Colorectal Cancer pipeline insights @ https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Metastatic Colorectal Cancer Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Metastatic Colorectal Cancer Therapeutics Market.

Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report

DelveInsight's Metastatic Colorectal Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Metastatic Colorectal Cancer treatment.
Key Metastatic Colorectal Cancer companies such as Amgen, Pfizer, Nurix Therapeutics Inc, Sumitomo Dainippon Pharma Oncology, Novocure, Processa Pharmaceuticals, Daiichi Sankyo, Qilu Pharmaceutical Co., Ltd., Binhui Biopharmaceutical, Parasol Biotech, Syndax Pharmaceuticals, Innovative Cellular Therapeutics, Immvira Pharma, ISA Pharmaceuticals, Jiangsu Hengrui Medicine, Peptomyc, Xbrane, TransCode Therapeutics, Servier, Jemincare, XBiotech, and others are evaluating new drugs for Metastatic Colorectal Cancer to improve the treatment landscape.
Promising Metastatic Colorectal Cancer pipeline therapies in various stages of development include Lumakras (sotorasib), Axitinib, NX 1607, TP-1454, and others.

Metastatic Colorectal Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Metastatic Colorectal Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Colorectal Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Metastatic Colorectal Cancer market.

Download our free sample page report on Metastatic Colorectal Cancer pipeline insights @ https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Metastatic Colorectal Cancer Emerging Drugs

Lumakras (sotorasib): Amgen
Axitinib: Pfizer
NX 1607: Nurix Therapeutics Inc
TP-1454: Sumitomo Dainippon Pharma Oncology

Metastatic Colorectal Cancer Companies

Over 80 key companies are involved in developing therapies for metastatic colorectal cancer. Among them, Amgen is one of the companies with drug candidates for metastatic colorectal cancer in the most advanced stage, specifically Phase III.

DelveInsight's report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Metastatic Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Metastatic Colorectal Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Metastatic Colorectal Cancer Therapies and Key Companies: Metastatic Colorectal Cancer Clinical Trials and advancements @ https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Metastatic Colorectal Cancer Pipeline Therapeutic Assessment
• Metastatic Colorectal Cancer Assessment by Product Type
• Metastatic Colorectal Cancer By Stage
• Metastatic Colorectal Cancer Assessment by Route of Administration
• Metastatic Colorectal Cancer Assessment by Molecule Type

Download Metastatic Colorectal Cancer Sample report to know in detail about the Metastatic Colorectal Cancer treatment market @ Metastatic Colorectal Cancer Therapeutic Assessment @ https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Metastatic Colorectal Cancer Current Treatment Patterns
4. Metastatic Colorectal Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Metastatic Colorectal Cancer Late-Stage Products (Phase-III)
7. Metastatic Colorectal Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Metastatic Colorectal Cancer Discontinued Products
13. Metastatic Colorectal Cancer Product Profiles
14. Metastatic Colorectal Cancer Key Companies
15. Metastatic Colorectal Cancer Key Products
16. Dormant and Discontinued Products
17. Metastatic Colorectal Cancer Unmet Needs
18. Metastatic Colorectal Cancer Future Perspectives
19. Metastatic Colorectal Cancer Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Metastatic Colorectal Cancer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.